Take-at-home tablet for MS approved for wider NHS rollout
A take-at-home tablet for multiple sclerosis (MS) is set to be more broadly rolled out on the NHS, potentially benefiting ...
pharmaphorum1d
Merck MS tablet set for wider use by NHS in England
The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...
Medical Marketing & Media2d
Selma Blair collabs with EMD Serono for DTC campaign about relapsing MS
The Merck KGaA collaborated with actress and patient advocate Selma Blair for the I’m Ready campaign. When EMD Serono embarked on a campaign to empower patients living with relapsing multiple ...
pharmaphorum1mon
Regulators finally back Merck KGaA oral MS drug
Europe’s CHMP top scientific committee gave a positive opinion for approval to cladribine, with the proposed trade name Mavenclad, for relapsing forms of MS with high disease activity.
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
FiercePharma21d
Merck KGaA's EMD Serono taps Selma Blair to join long-running campaign for MS drug Mavenclad
No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. Blair, best known for her roles in turn ...
Trade Arabia7mon
Merck's drug for multiple sclerosis wins UAE approval
US pharma group Merck said the UAE Ministry of Health and Prevention has approved the registration of its Mavenclad (cladribine tablets) for the treatment of adult patients with highly active ...